Urolithin A is a compound produced when gut bacteria metabolize ellagitannins — polyphenol precursors found in pomegranates, walnuts, and certain berries. It has attracted serious scientific attention primarily for its ability to stimulate mitophagy, the cellular process that identifies and removes damaged mitochondria. Because mitochondrial dysfunction is a consistent feature of aging neurons and multiple neurodegenerative diseases, researchers have begun asking whether urolithin A’s effects on mitochondrial quality control might extend to the brain.
A meaningful cluster of preclinical studies published between 2019 and 2025 has examined urolithin A in cell cultures and animal models of Alzheimer’s disease, Parkinson’s disease, stroke, and neuroinflammation. It is important to be direct about what this means: nearly all of this evidence comes from laboratory and animal settings. No large, well-powered human clinical trials have established whether urolithin A improves cognition or protects against neurodegeneration in people. What follows is an honest summary of the early science, what mechanisms have been proposed, and where significant uncertainty remains.
Key Takeaways
- Urolithin A stimulates mitophagy — the removal of damaged mitochondria — a process that preclinical research has linked to reduced amyloid, tau, and neuroinflammatory pathology in animal models.
- Animal and cell studies have found urolithin A-relevant effects across multiple neurological conditions including Alzheimer’s, Parkinson’s, stroke, and retinal neurodegeneration; human clinical trial evidence for brain outcomes is currently absent.
- The gut-brain axis is a plausible indirect route for some of urolithin A’s potential brain effects, given that it is produced by gut microbiota and research has identified gut-to-brain signaling mechanisms.
- Blood-brain barrier penetration and individual variability in urolithin A production are genuine scientific obstacles that researchers are actively working to address.
- A polyphenol-rich diet that supports urolithin production was associated with reduced brain atrophy in one human RCT, though the effect cannot be attributed to urolithin A specifically.
Why Mitophagy Is Central to the Brain Health Conversation
Neurons are among the most energy-demanding and longest-lived cells in the body. They depend heavily on healthy mitochondria to sustain function across decades. When mitochondria become damaged — through oxidative stress, metabolic disruption, or the accumulation of misfolded proteins — they can stop generating energy efficiently and begin releasing signals that harm surrounding tissue. Mitophagy is the quality-control mechanism that clears these dysfunctional mitochondria before they cause broader cellular damage.
The link between declining mitophagy and neurodegeneration became sharply clearer with a 2019 study in Nature Neuroscience, which demonstrated that stimulating mitophagy inhibited amyloid-β and tau pathology and reversed cognitive deficits across multiple animal models of Alzheimer’s disease [1]. That finding helped establish mitophagy induction as a scientifically plausible therapeutic target and is a primary reason urolithin A — a well-characterized mitophagy inducer — has attracted attention in neuroscience.
More recent work has refined how urolithin A engages this process. A 2025 study in Autophagy found that urolithin A modulates inter-organellar communication through a calcium-dependent mitophagy mechanism, with effects the authors linked to healthy ageing outcomes at the cellular level [11]. Research in diabetes-associated cognitive dysfunction has separately shown that restoring the mitochondrial fission-mitophagy balance in neurons can alleviate cognitive impairment in animal models [5], providing additional context for why mitochondrial quality control may be a meaningful target across multiple brain health conditions.
Alzheimer's Disease: Mechanistic and Preclinical Evidence
Multiple lines of preclinical research have examined whether urolithin A or its pathway can influence the molecular hallmarks of Alzheimer’s disease. Beyond the foundational mitophagy-and-amyloid work [1], a 2021 study in Cell Death and Differentiation investigated what happens when neurons are exposed to high-glucose conditions that drive amyloid production. The researchers found that urolithin A suppressed amyloid accumulation by modulating TGM2-dependent contacts between the endoplasmic reticulum and mitochondria, and by restoring calcium homeostasis within neurons [2]. Disrupted calcium regulation between these organelles is thought to contribute to neuronal vulnerability in both metabolic disease and Alzheimer’s pathology.
A 2025 review in Biomedicines surveyed the broader landscape of urolithin A research across central nervous system disorders. The authors concluded that the mechanistic rationale for studying urolithin A in Alzheimer’s and other neurodegenerative diseases is genuinely strong, while identifying significant obstacles to clinical translation — including marked individual variability in urolithin A production from food and uncertainty about optimal dosing for CNS applications [10]. All positive findings discussed in this review were derived from preclinical models.
Parkinson's Disease: Early Findings in Animal Models
Parkinson’s disease involves progressive loss of dopaminergic neurons, and mitochondrial dysfunction is considered a central feature of its pathology. A 2023 review in Antioxidants examined the prospects for urolithin A as a Parkinson’s disease intervention, highlighting its mitophagy induction, antioxidant activity, and anti-inflammatory properties as mechanistically relevant to the disease process [4]. The authors were candid that encouraging preclinical signals had not yet been tested in human clinical trials.
A 2025 study in Experimental Neurology extended this picture by looking at cognitive outcomes specifically. Using a Parkinson’s disease mouse model, the researchers reported that urolithin A improved Parkinson’s-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity [9]. This is a notable finding because cognitive decline in Parkinson’s disease is common and often undertreated. The study suggests urolithin A may affect cognitive function as well as motor pathology — though replication in human populations will be required before drawing clinical conclusions.
Neuroinflammation and Acute Brain Injury
Researchers have also investigated urolithin A in settings of acute neurological injury. A 2025 study in Neuropharmacology tested urolithin A in a mouse model of intracerebral hemorrhage — a severe form of stroke — and reported neuroprotective effects [8]. Intracerebral hemorrhage triggers rapid neuronal death partly through inflammation and oxidative stress, two processes urolithin A has shown activity against in other contexts.
Microglial cells — the brain’s resident immune cells — are a separate target of active research. A 2026 paper in Biomaterials described a nose-to-brain nanomotor delivery system engineered to target microglial mitophagy in neuroinflammation using urolithin A [12]. This represents experimental delivery research, not a clinical product, but it reflects a genuine scientific obstacle: getting sufficient urolithin A across the blood-brain barrier from systemic circulation is a challenge that has not been fully solved.
Urolithin A has shown activity in retinal neurons as well, which form part of the central nervous system. A 2024 study in Molecular Neurodegeneration found that urolithin A promoted lysophagy — the selective clearance of damaged lysosomes, a cellular waste-processing compartment — to prevent acute retinal neurodegeneration in animal models [6]. This extends urolithin A’s apparent cellular housekeeping effects beyond mitophagy alone.
The Gut-Brain Axis and Urolithin A
Because urolithin A is itself a product of gut microbial metabolism, its relationship to the brain must be understood partly through the gut-brain axis — the bidirectional communication system linking the gastrointestinal tract and central nervous system. A 2024 review in Nutrients examined the molecular basis for how urolithin A activates gut-brain interactions, identifying microbiota composition modulation, anti-inflammatory gut signaling, and effects on the enteric nervous system as plausible indirect routes by which urolithin A might influence brain health [7]. Some of urolithin A’s observed brain effects may therefore be mediated through the gut rather than through direct action on neural tissue.
A 2022 human randomized controlled trial — the DIRECT PLUS study published in the American Journal of Clinical Nutrition — found that a high-polyphenol Mediterranean diet was associated with reduced age-related brain atrophy compared to a standard Mediterranean diet over 18 months [3]. It is essential to note that this study tested a whole dietary pattern rich in ellagitannin-containing foods — not urolithin A in isolation. It cannot be used to attribute brain benefits specifically to urolithin A. It does, however, provide some human-level context for what diets that promote urolithin production might do over time, and it supports ongoing research into the broader polyphenol-gut-brain connection.
Key Limitations and What Comes Next
The honest picture is that the preclinical case for urolithin A having brain-relevant biological effects is scientifically coherent and growing — but it rests almost entirely on cell cultures and animal models. Cognitive and neuroprotective findings in mice have historically failed to translate to humans at a high rate, a challenge that has frustrated many promising neurological compounds over the past two decades.
Additional complications are specific to urolithin A. Not everyone’s gut microbiome efficiently converts ellagitannins into urolithin A, meaning blood levels vary substantially across individuals eating the same foods. Getting adequate concentrations across the blood-brain barrier from standard oral doses remains an unresolved challenge, and optimal dosing parameters for neurological applications have not been established. The 2025 Biomedicines review identified these explicitly as obstacles to CNS translation [10]. Standardized urolithin A supplements have human safety data — primarily in the context of muscle health and metabolic outcomes — but whether those doses reach the brain at therapeutically relevant concentrations is not yet known.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - DoNotAge Pure Urolithin A
capsules, 250-500 mg — Popular longevity-brand generic, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
Almost all evidence connecting urolithin A to brain health comes from cell cultures and animal models; human clinical trials specifically examining neurological or cognitive outcomes have not been published, and preclinical findings frequently do not replicate in people. Urolithin A supplements should not be considered a treatment for any neurological condition — consult a qualified physician before use, particularly if you have or are at risk for a neurodegenerative disease.
Frequently Asked Questions
What is the proposed connection between urolithin A and Alzheimer's disease?
The main proposed mechanism is mitophagy induction. A 2019 Nature Neuroscience study demonstrated that stimulating mitophagy inhibited amyloid-β and tau pathology and reversed cognitive deficits in animal models of Alzheimer’s disease [1]. A subsequent cell study found urolithin A suppressed neuronal amyloid production by stabilizing mitochondria-ER contacts and restoring calcium homeostasis [2]. These are preclinical findings, not human clinical results.
Has urolithin A been studied in Parkinson's disease?
Yes, in preclinical models. A 2025 study reported that urolithin A improved cognitive impairment in a Parkinson’s disease mouse model by reducing neuroinflammation and supporting neuroplasticity [9]. A 2023 review also assessed its mechanistic case for Parkinson’s, highlighting mitophagy induction and antioxidant effects as relevant to the disease [4]. No human clinical trials in Parkinson’s patients have been published to date.
Can urolithin A cross the blood-brain barrier?
This is an active and unresolved research question. Some researchers are developing specialized delivery approaches — such as a nose-to-brain nanomotor system described in a 2026 Biomaterials paper — specifically to improve CNS delivery of urolithin A [12]. Whether standard oral supplement doses reach the brain in concentrations sufficient to replicate cell or animal study effects has not been established in humans.
Does diet influence urolithin A's potential brain effects?
Indirectly, yes. Urolithin A is produced by gut bacteria from ellagitannins in pomegranates, walnuts, and berries, so diet affects how much your body produces. A human randomized controlled trial found that a high-polyphenol Mediterranean diet was associated with reduced age-related brain atrophy over 18 months compared to a standard Mediterranean diet [3]. This study tested the whole dietary pattern, however, and its results cannot be attributed solely to urolithin A.
What is lysophagy and how does urolithin A relate to it?
Lysophagy is the cellular process of clearing damaged lysosomes — compartments responsible for digesting cellular waste — and it is related to but distinct from mitophagy. A 2024 study in Molecular Neurodegeneration found that urolithin A promoted lysophagy to protect retinal neurons from acute degeneration in an animal model [6]. This suggests urolithin A supports cellular housekeeping through more than one pathway, though all evidence remains preclinical.
Who should be cautious about urolithin A supplements?
Anyone with an existing neurological condition should consult a physician before using urolithin A supplements, as the evidence for brain benefits is preclinical and no approved therapeutic use exists. People with conditions that affect gut microbiome function may produce less urolithin A from food, and the same may apply to urolithin A supplements in ways not yet fully characterized. The 2025 CNS review noted that individual variability and dosing remain significant open questions [10].
References
- Fang EF et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nature neuroscience (2019). PMID 30742114
- Lee HJ et al. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis. Cell death and differentiation (2021). PMID 32704090
- Kaplan A et al. The effect of a high-polyphenol Mediterranean diet (Green-MED) combined with physical activity on age-related brain atrophy: the Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed Study (DIRECT PLUS). The American journal of clinical nutrition (2022). PMID 35021194
- Wojciechowska O et al. Urolithin A in Health and Diseases: Prospects for Parkinson's Disease Management. Antioxidants (Basel, Switzerland) (2023). PMID 37508017
- Tang W et al. Neuron-targeted overexpression of caveolin-1 alleviates diabetes-associated cognitive dysfunction via regulating mitochondrial fission-mitophagy axis. Cell communication and signaling : CCS (2023). PMID 38102662
- Jiménez-Loygorri JI et al. Urolithin A promotes p62-dependent lysophagy to prevent acute retinal neurodegeneration. Molecular neurodegeneration (2024). PMID 38890703
- Kubota D et al. Activation of the Gut-Brain Interaction by Urolithin A and Its Molecular Basis. Nutrients (2024). PMID 39408336
- Guo Y et al. Neuroprotective effects of urolithin a in a mouse model of intracerebral hemorrhage. Neuropharmacology (2025). PMID 40449618
- Xu N et al. Urolithin A improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity. Experimental neurology (2025). PMID 40714019
- Zhang Q et al. Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges. Biomedicines (2025). PMID 40722629
- Roussos A et al. Urolithin Α modulates inter-organellar communication via calcium-dependent mitophagy to promote healthy ageing. Autophagy (2025). PMID 40944367
- Fu Y et al. A 3-N nose-to-brain urolithin a nanomotor targeting microglial mitophagy in neuroinflammation. Biomaterials (2026). PMID 41980377
